USTC achieves electrical manipulation of spin filling sequence in bilayer graphene based quantum dots
Peer-Reviewed Publication
Updates every hour. Last Updated: 20-Jun-2025 07:10 ET (20-Jun-2025 11:10 GMT/UTC)
A team led by Prof. Guo Guangcan from the University of Science and Technology of China (USTC) has demonstrated the ability to electrically manipulate the spin filling sequence in a bilayer graphene (BLG) quantum dot (QD). This achievement, published in Physical Review Letters, showcases the potential to control the spin degree of freedom in BLG, a material with promising applications in quantum computing and advanced electronics.
A team of researchers from the University of Science and Technology of China (USTC) has recently developed a lightweight prosthetic hand with 19 degrees of freedom (DOF), capable of replicating human hand functions. This development can assist in the functional rehabilitation and daily activities of millions of upper-limb amputees. The research was published in Nature Communications.
This review investigates the potential of mesenchymal stem cells (MSCs) and their secreted extracellular vesicles (EVs) as therapeutic tools for regulating CD4+T cells in immune diseases. MSCs possess unique properties, including multilineage differentiation and immunomodulation, making them promising candidates for treating immune-related disorders.
Researchers have discovered various topological structures in water waves (skyrmions, merons, Möbius and vortices with different topological charges), observed manipulation of floating particles using topological water waves, and described how the spin-orbital motion of particle is related to topologies of waves.
Atherosclerosis, a disease characterized by the accumulation of lipids and inflammatory cells in the arterial wall, is a significant cause of cardiovascular events. A key process in atherosclerosis is the endothelial-to-mesenchymal transition (EndMT), which involves the transformation of endothelial cells into mesenchymal cells, contributing to plaque formation and vascular dysfunction. The novel anthraquinone compound Kanglexin (KLX) has been investigated for its potential to prevent EndMT in atherosclerosis by targeting the fibroblast growth factor receptor 1 (FGFR1) and suppressing the integrin β1/transforming growth factor-beta (TGFβ) signaling pathway. This study provides insights into the molecular mechanisms underlying the protective effects of KLX against EndMT and atherosclerotic progression.